{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:28:11Z","timestamp":1783524491948,"version":"3.55.0"},"reference-count":34,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2015,4,9]]},"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Randomised controlled trials (RCTs) have given contradictory results about the efficacy and safety of ibandronate in treating metastatic bone disease (MBD) or multiple myeloma. This review meta-analysed the literature to gain a more comprehensive picture.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis of ibandronate compared with placebo or zoledronate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>PubMed, EMBASE and the Cochrane Library databases were systematically searched to identify RCTs published up to March 2015 evaluating ibandronate to treat MBD or multiple myeloma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Review method<\/jats:title>\n                    <jats:p>10 RCTs involving 3474 patients were included. Six RCTs were placebo-controlled and four compared ibandronate with zoledronate. The studies included in this review were mainly from European countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Intravenous ibandronate (6\u2005mg) or oral drug (50\u2005mg) decreased the risk of skeletal-related events compared to placebo (risk ratio (RR) 0.80, 95% CI 0.71 to 0.90, p=0.002). It also reduced the bone pain score below baseline significantly more than did placebo at 96\u2005weeks (weighted mean difference \u22120.41, 95% CI \u22120.56 to \u22120.27, p&lt;0.001). The incidence of diarrhoea, nausea and adverse renal events was similar between the ibandronate and placebo groups, but ibandronate was associated with greater risk of abdominal pain. Ibandronate was associated with similar risk of skeletal-related events as another bisphosphonate drug, zoledronate (RR 1.02, 95% CI 0.82 to 1.26, p=0.87). The incidence of nausea, jaw osteonecrosis and fatigue was similar for the two drugs, but the incidence of adverse renal events was significantly lower in the ibandronate group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ibandronate significantly reduces the incidence of skeletal-related events and bone pain in patients with MBD or multiple myeloma relative to placebo. It is associated with a similar incidence of skeletal-related events as zoledronate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2014-007258","type":"journal-article","created":{"date-parts":[[2015,6,3]],"date-time":"2015-06-03T12:27:42Z","timestamp":1433334462000},"page":"e007258","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials"],"prefix":"10.1136","volume":"5","author":[{"given":"Chun-Jing","family":"Geng","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liang","sequence":"additional","affiliation":[{"name":"Postgraduate School of Guangxi Medical University, Nanning, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hong","family":"Zhong","sequence":"additional","affiliation":[{"name":"Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan-Ying","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Affiliated Hospital of Chifeng University, Inner Mongolia Autonomous Region, Nanning, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin-Yi","family":"Yuan","sequence":"additional","affiliation":[{"name":"Out-patient Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2015,6,2]]},"reference":[{"key":"2025121600575271000_5.6.e007258.1","doi-asserted-by":"publisher","DOI":"10.1053\/ctrv.2000.0210"},{"key":"2025121600575271000_5.6.e007258.2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0931"},{"key":"2025121600575271000_5.6.e007258.3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0093-7754(01)90229-5","article-title":"Bone metastases: approaches to management","volume":"28","author":"Janjan","year":"2001","journal-title":"Semin Oncol"},{"key":"2025121600575271000_5.6.e007258.4","first-page":"895","article-title":"Therapy of metastatic bone pain","volume":"42","author":"Serafini","year":"2001","journal-title":"J Nucl Med"},{"key":"2025121600575271000_5.6.e007258.5","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"2025121600575271000_5.6.e007258.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra030831"},{"key":"2025121600575271000_5.6.e007258.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1007"},{"key":"2025121600575271000_5.6.e007258.8","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","article-title":"Current use of bisphosphonates in oncology. International Bone and Cancer Study Group","volume":"16","author":"Body","year":"1998","journal-title":"J Clin Oncol"},{"key":"2025121600575271000_5.6.e007258.9","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.1998.16.3.1218","article-title":"Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review","volume":"16","author":"Bloomfield","year":"1998","journal-title":"J Clin Oncol"},{"key":"2025121600575271000_5.6.e007258.10","doi-asserted-by":"publisher","DOI":"10.3928\/01477447-20090301-13"},{"key":"2025121600575271000_5.6.e007258.11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejcsup.2004.01.003","article-title":"Pharmacokinetic and clinical equivalence of oral and intravenous ibandronate for metastatic bone disease","volume":"2","author":"Leyland-Jones","year":"2004","journal-title":"EJC Suppl"},{"key":"2025121600575271000_5.6.e007258.12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601663"},{"key":"2025121600575271000_5.6.e007258.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2354.2007.00808.x"},{"key":"2025121600575271000_5.6.e007258.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.032"},{"key":"2025121600575271000_5.6.e007258.15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/pme.12016","article-title":"Zoledronate for metastatic bone disease and pain: a meta-analysis of randomized clinical trials","volume":"14","author":"Zhu","year":"2013","journal-title":"Pain Med"},{"key":"2025121600575271000_5.6.e007258.16","first-page":"524","article-title":"Impact of zoledronic acid on renal function in patients with cancer: clinical significance and development of a predictive model","volume":"4","author":"McDermott","year":"2006","journal-title":"J Support Oncol"},{"key":"2025121600575271000_5.6.e007258.17","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5414\/CP201823","article-title":"Risk factors for renal impairment in patients with solid tumors or multiple myeloma treated with zoledronic acid","volume":"51","author":"Cha","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2025121600575271000_5.6.e007258.18","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1159\/000132707","article-title":"Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases","volume":"80","author":"Joensuu","year":"2008","journal-title":"Urol Int"},{"key":"2025121600575271000_5.6.e007258.19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00044011-200626060-00002","article-title":"Long-term safety of intravenous ibandronic acid for up to 4years in metastatic breast cancer: an open-label trial","volume":"26","author":"Pecherstorfer","year":"2006","journal-title":"Clin Drug Investig"},{"key":"2025121600575271000_5.6.e007258.20","unstructured":"Higgins JPT , Green S . Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). 2013."},{"key":"2025121600575271000_5.6.e007258.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.03.025"},{"key":"2025121600575271000_5.6.e007258.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2354.2008.00980.x"},{"key":"2025121600575271000_5.6.e007258.23","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008386501738"},{"key":"2025121600575271000_5.6.e007258.24","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-010-0179-x"},{"key":"2025121600575271000_5.6.e007258.25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4103\/0973-1075.92338","article-title":"A randomized controlled trial to compare the efficacy of bisphosphonates in the management of painful bone metastasis","volume":"17","author":"Choudhury","year":"2011","journal-title":"Indian J Palliat"},{"key":"2025121600575271000_5.6.e007258.26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm119"},{"key":"2025121600575271000_5.6.e007258.27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70539-4"},{"key":"2025121600575271000_5.6.e007258.28","doi-asserted-by":"crossref","unstructured":"Wong MH , Stockler MR , Pavlakis N . Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2012;(2):CD003474. doi:10.1002\/14651858.CD003474","DOI":"10.1002\/14651858.CD003474.pub3"},{"key":"2025121600575271000_5.6.e007258.29","doi-asserted-by":"crossref","unstructured":"Yuen KK , Shelley M , Sze WM , et al . Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev 2006;(18):CD006250. doi:10.1002\/14651858.CD006250","DOI":"10.1002\/14651858.CD006250"},{"key":"2025121600575271000_5.6.e007258.30","first-page":"2985","article-title":"Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis","volume":"20","author":"Lopez-Olivo","year":"2012","journal-title":"Support Care Cancer"},{"key":"2025121600575271000_5.6.e007258.31","doi-asserted-by":"crossref","unstructured":"Mhaskar R , Redzepovic J , Wheatley K , et al . Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev 2012;(5):CD003188. doi:10.1002\/14651858.CD003188","DOI":"10.1002\/14651858.CD003188.pub3"},{"key":"2025121600575271000_5.6.e007258.32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2275"},{"key":"2025121600575271000_5.6.e007258.33","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200626010-00006"},{"key":"2025121600575271000_5.6.e007258.34","first-page":"1797","article-title":"Lack of difference in acute nephrotoxicity of intravenous bisphosphonates zoledronic acid and ibandronate in women with breast cancer and bone metastases","volume":"35","author":"Luedders","year":"2015","journal-title":"Anticancer Res"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2014-007258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:58:06Z","timestamp":1765875486000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2014-007258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,6,2]]},"published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1136\/bmjopen-2014-007258"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2014-007258","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}